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Whither core outcome sets?Core outcome sets are becoming a burgeoning area of
clinical epidemiology research. There are varying defini-
tions and terminologies used, but the agreed elements of a
core outcome set are captured in the following definition:
an agreed standardized set of outcome domains with at least
one instrument in each domain that should be measured and
reported, as a minimum, for use in primary randomized/
observational studies and systematic reviews, addressing
effectiveness questions in health or health care. The
OMERACT (Outcome Measures in Rheumatology) group
has been developing these since 1992 [1]; interest has
recently increased with the attention given to selective
reporting by groups such as CONSORT, PRISMA,
ClinicalTrials.gov [2], the alltrials initiative (http://www.
alltrials.net/), plus the need for agreement on a parsimonious
list of patient important outcomes for systematic reviews
and guidelines championed by the Cochrane Collaboration.
The Cochrane Collaboration Systematic Reviews now have
moved the key table of results [the Summary of Findings
table (http://handbook.cochrane.org/)] from the back of the
review to the front pagedthis permits only up to seven
patient-important outcomes that should include both bene-
fits and harms. Systematic reviews of interventions by differ-
ent groups within the Cochrane Collaboration (declaration
of interest: PT coleads one of these groupsdthe Cochrane
Musculoskeletal Review Group) for the same condition,
such as fibromyalgia or osteoarthritis, currently present a
wide range of different outcomes in these summary of find-
ings tables that patient, clinician, policymaker, and reader
have indicated are just too confusing. In contrast, this has
been addressed successfully in rheumatoid arthritis where
the OMERACT core outcome set or a derivative has been
adopted by international agencies with a resulting increase
in their adoption in the primary studies [3,4]. The GRADE
recommendations likewise have formalized a process,
whereby they identify the critical patient-important out-
comes. The Core Outcome Measures in Effectiveness Trials
(COMET) [5] initiative [http://www.comet-initiative.org/]
has taken this to the next level providing a home for dis-
course between over 100 groups around the world across
all subject areas; meetings have been held in Europe and
North America for information exchange between core set
developers across different disciplines. Annual COMET
meetings are held that provide an important forum for clin-
ical epidemiologists to meet core set development research-
ers from other disciplines and with the other stakeholders0895-4356  2014 Elsevier Inc.
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Open access under CC BY-NC-ND license.including patients, research approval and commissioning
agencies, guideline groups, relevant governmental agencies
[eg, FDA, National Libraries], journal editors, industry, etc.
In this issue, Boers et al. present a conceptual framework
that encompasses the complete content of what is measure-
able in an effectiveness study, including both patient-
centered and intervention-specific information. The
framework comprises three core ‘‘Areas’’, Death, Life Im-
pact, and Pathophysiologic Manifestations, and a further
one. Resource Use is strongly recommended. ACore Set de-
velopment for all Patients/Population, Intervention, Compa-
rators, Outcomes (PICOs) [6] of similar interventions for
any specific health condition starts by identifying at least
one core ‘‘Domain’’ within each of the Areas to formulate
the ‘‘Core Domain Set.’’ Next, at least one applicable meas-
urement instrument for each core Domain is identified to
formulate a ‘‘Core Outcome Measurement Set.’’ For applic-
ability, each instrument must prove to be truthful (valid),
discriminative, and feasible. This article is also accompa-
nied by a slide set, the first in a new option offered to authors
by Journal of Clinical Epidemiology (JCE) that we encour-
age future authors to complete as we believe that this will
facilitate the dissemination of these articles. Five other
articles in this issue address aspects of Bias:
Several articles address different biases.
First, can a panel of experts successfully adjust the effect
sizes of observational studies included in systematic
reviews of interventions for the biases judged of concern
using an idealized/target study protocol? Hak et al. describe
an intriguing novel approach to using expert judgment to
adjust a systematic review of observational studies for
threats to the validity of their effect size estimates. Five
quantitatively trained assessors (four trained in epidemiol-
ogy and one trained in medical statistics) adjusted the effect
sizes of a systematic review of observational studies of in-
terventions for the biases judged of concern using an ideal-
ized/target study protocol; the example was a conventional
meta-analysis assessing seasonal influenza vaccine effec-
tiveness among community-dwelling elderly aged 60 years
and older. The idealized target study was defined with re-
spect to the population, which the researchers planned to
study (eg, community-dwelling elderly), their planned
comparison (eg, seasonal influenza vaccination vs. no vac-
cination), and the outcome, which they planned to measure.
Potential biases in the studies that were included in the sys-
tematic review were identified using bias checklists. The
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these experts and adjustments applied to the point estimates
and confidence intervals, using an easy to use simple scale
shown in the article. The point estimates did not change
substantively (all less than 5%), but the confidence limits
did widen; furthermore, a welcome result was that the
between-study heterogeneity was reduced. This approach
needs to be validated in a situation where there is also an
‘‘ideal target study’’ as a criterion to compare this strategy
to; there are also many variables in this that would each
need assessing if this is to be used for decision making.
Second, Fleming et al. demonstrate that systematic re-
views published in higher impact clinical journals are of
higher quality, when quality is analyzed by unit of Impact
Factor. Over the 6-month period, 327 interventional sys-
tematic reviews were identified (from the Core Clinical
Journals in MEDLINE via PubMed), with a mean AM-
STAR score of 63.3% (standard deviation, 17.1%), when
converted to a percentage scale. Systematic reviews pub-
lished in higher impact journals were undertaken more rig-
orously with higher percentage AMSTAR scores. Overall,
45 systematic reviews (13.8%) were rated as low quality
with an original AMSTAR score of 14; 65.8% (215 SRs)
were fair (5e8 original AMSTAR score), and 21% (67
SRs) were scored as good (O9 original AMSTAR score).
For every unit increase of Impact Factor, the percentage
AMSTAR score increased by 0.68%. The authors found
that the involvement of a methodologist or statistician
and inclusion of a meta-analysis as part of the review proc-
ess were also associated with better methodological stand-
ards. Individual AMSTAR items that were poorly addressed
in lower impact journals included use of a priori design
or reference to a protocol, use of the publication status as
a selection criterion for inclusion of relevant studies in
the review, assessment of publication bias, and clarification
of conflict of interest.
In the third article on bias, Gopalakrishna introduce the
first article from the GRADE group describing the applica-
tion of Recommendations Assessment, Development and
Evaluation (GRADE) to diagnostic tests, and it’s use in Co-
chrane diagnostic test accuracy reviews. They applied this
approach to three Cochrane reviews with the aim of better
understanding the application of the GRADE criteria to
such reviews. It was challenging but doable. This exercise
nicely addressed the pivotal issue of ensuring that assessors
looked at the evidence from a patient-important outcome
perspective rather than a test accuracy standpoint.
Fourth, Guyatt et al. argue that blinded interpretation
of study results by either the investigators or an external
authority can feasibly and effectively diminish interpreta-
tion bias. They implemented this in the reporting of a multi-
center randomized controlled trial (RCT) comparing the
treatment of tibial shaft fractures with reamed or unreamed
intramedullary nails. The approach involved developing
two interpretations of the results on the basis of a blinded
review of the primary outcome data (experimentaltreatment A compared with control treatment B). One inter-
pretation assumes that A is the experimental intervention
and another assumes that A is the control. After agreeing
that there will be no further changes, the investigators re-
cord their decisions and sign the resulting document. The
randomization code is then broken, the correct interpreta-
tion chosen, and the manuscript finalized. This is more
practical in being less time consuming than the previous
proposals by Gotsche [7] and Pocock [8] that entailed draft-
ing pairs of manuscripts or proposals for each alternative.
Fifth, Galenkamp et al. investigated underreporting and
overreporting biases, They examined the reported increases
in the prevalence of chronic diseases in older people in
most countries. This study investigated if a changed incli-
nation to report diseases underlies these increases by com-
paring the agreement between self-reports and general
practitioner records of chronic diseases in over 50,000 indi-
viduals between 1992/1993 and 2008/2009. They found
that trends in self-reported chronic diseases were influenced
by changes in reporting behavior. Overreporting of chronic
diseases became significantly more common over time,
whereas underreporting became less common.
Whether and how to include the time dimension in
scales is a continuing debate. As Marfeo et al. summarize
it, because severity of mental conditions often fluctuates
over time, the use of an ‘‘agreement rating scale’’ allows
respondents to reflect on their typical functioning rather
than referencing a specific time frame. Marfeo investigated
this with work disability scales comparing an ‘‘agreement’’
rating scale (a four-point rating scale ranging from
‘‘strongly disagree’’ to ‘‘strongly agree’’) with a ‘‘fre-
quency’’ scale (a five-point rating scale ranging from
‘‘never’’ to ‘‘always’’). Frequency-based items performed
better in the normal range of responses of behaviors; the
agreement items did better with attitudes.
Sarkadia et al. use the data from a parenting program to
demonstrate the use of a novel approach used outcome
distribution curves to estimate the population-level impact
of a public health intervention. The area between the two
overlapping distribution curves at baseline and follow-up
represents the impact of the intervention. This allows anal-
ysis of inequitable effects; for example, in this case, the
larger benefit for the subgroup of parents with lower
education.
Two articles address issues around searching: ‘‘Citation
networks’’ and ‘‘citation islands’’ are relatively new terms
to the clinical epidemiology community that are attracting
increasing attention to address the unappreciated fact that
the primary publication of RCTs only cite as little as a third
of relevant preceding RCTs [9,10]. For systematic reviews,
the Cochrane Handbook recommends at a minimum an
electronic search of the Cochrane Central Register of Con-
trolled Trials (CENTRAL), MEDLINE, and EMBASE.
This still misses many trials. Therefore many recommend
searching the citations of all RCTs found to seek out other
RCTs. This still misses many RCTs of the same PICO
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complement the above. In this issue, Robinson et al. use ci-
tation networks with informative (and attractive) figures to
demonstrate that citation of related trials are often discon-
nected and argue for ‘‘bidirectional citation searches’’d
that is, by examining direct (referenced trials) and indirect
(through references of referenced trials with a provisional
recommendation for four cycles forward and backward in
citation searching). They examined 259 meta-analyses with
a total of 2,413 and a median of seven RCTs each. Just us-
ing citations in the RCTs found that references were miss-
ing in an amazing 54% of trials of specific questions at
least.
Second, Wright et al. provide a nice example to show
that searching MEDLINE is inadequate for multidiscipli-
nary topics and that searches of databases covering health
and social sciences, gray literature databases, non-
Western databases, personal libraries, and plus citation
tracking activities are needed. They used the example of de-
termining the optimal databases to search for studies of
faith-sensitive interventions for treating depression.
Two articles study clinimetric statistical issues: Cheung
et al. report on a nice clear exemplar of using both anchor-
and distribution-based approaches, to compute a reasonable
range for the minimal clinically important difference
(MCID) of the Functional Assessment of Cancer Therapy
Cognitive Function.
Schmidt et al. show that care is needed in the selection
of statistical tests to exploring interaction effects in small
samples. In small sample sizes, depending on the tests
chosen, type 1 error can be as high as 0.10. They reviewed
the literature on the performance of existing statistical tests.
A simulation confirmed the literature review conclusions.
The best test also depends on whether the summary statistic
is a risk difference (the LR and RERI-based tests performed
best) or an odds ratio (the Tarone and BD tests are
recommended).
In the letter section, there is an interesting debate on
merits and disadvantages of the stepped wedge designstimulated by the JCE article of Klotz et al.[11] addressing
the ongoing contentious issues of individual vs, clusters, as-
sessments over time of same versus different individuals;
sampling within a cluster to reduce measurement burden,
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